11.83
-1.43
(-10.78%)
At close: April 3 at 4:00:01 PM EDT
11.64
-0.19
(-1.61%)
Pre-Market: 8:00:02 AM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.38 | -0.39 | -1.63 | -2.14 |
| Low Estimate | -0.44 | -0.44 | -1.8 | -2.33 |
| High Estimate | -0.34 | -0.36 | -1.53 | -1.74 |
| Year Ago EPS | -- | -- | -4.05 | -1.63 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | 0.00% | 0.00% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.43 | -0.43 | -0.5 | -0.28 |
| EPS Actual | -- | -- | -1.6 | -0.39 |
| Difference | -- | -- | -1.1 | -0.11 |
| Surprise % | -- | -- | -220.00% | -38.05% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.38 | -0.39 | -1.63 | -2.14 |
| 7 Days Ago | -0.38 | -0.37 | -1.46 | -2 |
| 30 Days Ago | -0.38 | -0.37 | -1.46 | -2 |
| 60 Days Ago | -0.38 | -0.37 | -1.47 | -2.07 |
| 90 Days Ago | -0.38 | -0.37 | -1.47 | -2.07 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 2 |
| Up Last 30 Days | -- | -- | -- | 2 |
| Down Last 7 Days | -- | 1 | 2 | -- |
| Down Last 30 Days | 1 | 1 | 4 | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| BCAX | -- | -- | 59.81% | -31.49% |
| S&P 500 | 6.69% | 6.80% | 9.98% | 14.34% |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/13/2025 |
| Reiterates | Wedbush: Outperform to Outperform | 2/12/2025 |
| Initiated | Wedbush: Outperform | 2/6/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/27/2025 |
| Initiated | HC Wainwright & Co.: Buy | 12/6/2024 |
| Initiated | Cantor Fitzgerald: Overweight | 10/8/2024 |
Related Tickers
MBX MBX Biosciences, Inc.
6.37
-8.61%
ZBIO Zenas BioPharma, Inc.
7.80
-7.47%
KYMR Kymera Therapeutics, Inc.
23.69
-10.13%
RVMDW Revolution Medicines, Inc.
0.0400
+13.96%
AVBP ArriVent BioPharma, Inc.
16.94
-5.89%
MAZE Maze Therapeutics, Inc.
9.32
-10.13%
IMTX Immatics N.V.
3.8400
-7.91%
CRGX CARGO Therapeutics, Inc.
4.1000
-3.07%
ARTV Artiva Biotherapeutics, Inc.
2.5400
-11.19%
SION Sionna Therapeutics, Inc.
11.61
-1.86%